Physician profile
Alan E Selkin
NPI 1508912759
$6,581.11
in general payments reported to CMS, 2019-2025
32 companies · $1,319 in 2025
The $1,319 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,438 · 2020: $558 · 2021: $155 · 2022: $915 · 2023: $1,124 · 2024: $1,073 · 2025: $1,319.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,490 · Education: $25.25.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,490.49 |
| Education | $25.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,346.84 | 2019-2025 | Linzess, Viberzi, Rinvoq |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,228.24 | 2019-2025 | Xifaxan, Trulance |
| Takeda Pharmaceuticals U.S.A., INC. | $603.85 | 2019-2025 | Entyvio, Eohilia |
| Pfizer INC. | $577.61 | 2019-2025 | |
| Madrigal Pharmaceuticals | $400.62 | 2024-2025 | Rezdiffra, Resmetirom |
| Janssen Biotech, INC. | $344.39 | 2019-2025 | Stelara, Simponi Aria, Simponi |
| Ardelyx, INC. | $330.67 | 2022-2025 | Ibsrela |
| Genzyme Corporation | $289.75 | 2022-2025 | |
| Celgene Corporation | $191.89 | 2021-2024 | Zeposia |
| Ferring Pharmaceuticals INC. | $161.49 | 2019-2024 | Rebyota |
| Lilly USA, LLC | $148.59 | 2024-2025 | Omvoh |
| Gilead Sciences, INC. | $110.58 | 2019-2025 | |
| Allergan, INC. | $88.45 | 2019 | |
| Braintree Laboratories, INC. | $83.62 | 2020-2025 | Suflave, Sutab |
| Ucb, INC. | $80.35 | 2019 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Romark Laboratories, Lc | $72.50 | 2019 | |
| Intercept Pharmaceuticals, INC. | $68.12 | 2023 | Ocaliva |
| Ironwood Pharmaceuticals, INC | $65.16 | 2019-2023 | Linzess |
| Regeneron Healthcare Solutions, INC. | $63.91 | 2022-2024 | Dupixent |
| Qol Medical, LLC | $58.20 | 2019-2020 | |
| Redhill Biopharma INC. | $50.05 | 2020-2024 | Talicia |
| Merck Sharp & Dohme LLC | $44.20 | 2019-2023 | Dificid |
| Shire North American Group INC | $29.64 | 2019 | |
| Echosens North America, INC. | $25.00 | 2019 | |
| Medtronic, INC. | $22.99 | 2025 | Beacon |
| Intra-Sana Laboratories | $20.13 | 2025 | Reltone 400 Mg, Reltone 200 Mg, Glycate |
| Shionogi INC | $15.92 | 2020 | |
| Endo Pharmaceuticals INC. | $15.31 | 2020 | |
| Celltrion USA INC. | $14.97 | 2024 | Zymfentra |
| Amgen INC. | $14.49 | 2023 | Avsola, Amjevita |
| Micro-Tech Endoscopy USA, INC. | $13.58 | 2023-2024 | Blueboost, Balloons (Need Marketed Device Name) |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$77,759.52 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alan Selkin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.